Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.45 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20314193 | 0.89 | MEN1 (0.49) | BCHEMEN1KMT2AMAPK1HTT | |
| SCHEMBL20314122 | 0.88 | BCHE (0.41) | CXCR4BCHECD274 | |
| SCHEMBL21539208 | 0.86 | MRGPRX4 (0.43) | BCHEMEN1KMT2ASMN1; SMN2CD274 | |
| SCHEMBL20324511 | 0.85 | ANO1 (0.43) | CXCR4BCHEMEN1KMT2AMAPK1 | |
| SCHEMBL20324956 | 0.85 | SLC6A4 (0.41) | CXCR4BCHETP53MEN1KMT2A | |
| SCHEMBL20324496 | 0.85 | PIM1 (0.43) | BCHEMEN1KMT2A | |
| SCHEMBL20314119 | 0.85 | BCHE (0.52) | BCHEMEN1KMT2AMAPK1HTT | |
| SCHEMBL21539303 | 0.83 | BCHE (0.47) | CXCR4BCHECD274 | |
| SCHEMBL20314206 | 0.82 | MEN1 (0.46) | BCHEMEN1KMT2AMAPK1HTT | |
| SCHEMBL20314092 | 0.81 | MEN1 (0.43) | BCHEMEN1KMT2AMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | CXCR4 655/4885BCHE 2954/4885TP53 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.